Bluebird bio

With our lentiviral-based gene therapy and gene editing capabilities, we have built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapies for cancer. Our clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of transfusion-dependent ß-thalassemia (also known as ß-thalassemia major); a single-center Phase 1/2 study in France (HGB-205) for the treatment of transfusion-dependent ß-thalassemia or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of severe sickle cell disease (HGB-206). We also have ongoing preclinical CAR T immuno-oncology programs, as well as discovery research programs utilizing megaTAL/homing endonuclease gene editing technologies. Our gene therapy process involves extracting certain cell types from a patient, inserting genetic material into the patient’s own cells and then re-infusing the gene-modified cells back into the patient. For beta-thalassemia, sickle cell disease and adrenoleukodystrophy, we insert a functional copy of the target gene into the patient’s hematopoietic stem cells (HSCs), enabling patients to produce proteins that are otherwise missing or dysfunctional as a result of their hereditary disease. In oncology, the gene therapy process targets a different cell type, called T-cells. In this case, genetic sequences are inserted into a patient’s own T-cells to program the T cells to specifically recognize and attack cancer cells. bluebird bio’s approach represents a highly personalized therapy and a potential paradigm shift in the treatment of severe genetic and orphan diseases.
Type
Public
HQ
Cambridge, US
Founded
1992
Employees
254 (est)+78%
Bluebird bio was founded in 1992 and is headquartered in Cambridge, US

Key People at Bluebird bio

Jeffrey T. Walsh

Jeffrey T. Walsh

Chief Operating Officer
Mitchell H. Finer

Mitchell H. Finer

Chief Scientific Officer
Richard E. T. Smith

Richard E. T. Smith

Vice President, Investor Relations
Linda C. Bain

Linda C. Bain

Vice President, Finance and Business Operations
Cyrus Mozayeni

Cyrus Mozayeni

Senior Director, Business Development
Nick Leschly

Nick Leschly

CEO

Bluebird bio Locations

Cambridge, US
Paris, FR
Seattle, US

Bluebird bio Metrics

Bluebird bio Summary

Market capitalization

$2.39 B

Closing share price

$62.5
Bluebird bio's latest market capitalization is $2.39 B.

Bluebird bio Market Value History

Bluebird bio News

Bluebird bio Company Life

You may also be interested in